The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.
Audrey Andrews
Advertisement
Articles by Audrey Andrews
The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.
In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).
Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer
Advertisement
Latest Updated Articles
- ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients
Published: March 9th 2011 | Updated:
- ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma
Published: March 9th 2011 | Updated:
- ASH 2010: CPX-351 Improves Response in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Published: March 9th 2011 | Updated:
- SABCS Coverage: MA.27 Study Finds Exemestane and Anastrozole Comparable
Published: March 2nd 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
5